An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs Edaravone (Primary)
- Indications Amyotrophic lateral sclerosis; Cerebral infarction; Liver disorders; Stroke
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 14 Apr 2019 Status changed from recruiting to completed.
- 15 Nov 2018 Status changed from not yet recruiting to recruiting.
- 17 Sep 2018 New trial record